key: cord-0681875-2d15u9gn
authors: Yoshida, A.; Ikegami, T.; Igawa, K.
title: Two cases of anti‐TIF1‐γ antibody positive dermatomyositis with manifested symptoms after SARS‐CoV‐19 vaccination
date: 2022-03-17
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.18060
sha: f52f6ec25f5e72b3966b32a28e7d46e0ac2c8ba8
doc_id: 681875
cord_uid: 2d15u9gn

nan

(manufactured by Pfizer Inc., New York, NY, USA). Skin examination confirmed bilateral eyelid oedema and revealed e rythema with pruritus on both auricles and scaly erythema with pruritus from the posterior neck to the back of the head. In addition, periungual erythema on both fingers and erythema with slight hyperkeratosis at the bilateral metacarpophalangeal (MCP) joints, the extensor side of the right elbow joint, and the shoulder joint were noted (Fig. 1) . Other than mild fatigue, no remarkable abnormalities were found upon physical examination, including the manual muscle strength test (MMT). She had no obvious respiratory symptoms or dysphagia. Laboratory examination revealed high values of the muscle deviation enzyme, creatine kinase (CK): 3119 U/L (normal range of female: 41-153), myoglobin: 583.42 ng/mL (normal range: 109>) and aldolase: 16.5 mg/dL (normal range: 5>). Concerning DM-specific antibodies, only anti-transcription intermediary factor 1-gamma (anti-TIF1-c Ab) was positive. No obvious interstitial pneumonia was found by chest Xp. Histopathological findings of skin samples from erythema with slight hyperkeratosis at the extensor side of the right elbow joint revealed liquefaction degeneration in the basal layer and mild lymphocytic infiltration around small vessels at mid-dermis (Fig. 1 ). Histopathological findings of muscle (vastus lateralis muscle) were consistent with DM (not shown). Based on these results, she diagnosed as DM (anti-TIF1-c Ab positive).

A combination of prednisolone (PSL) 50 mg (1 mg/kg) and high-dose intravenous immunoglobulin therapy were administered. The general condition and myogenic enzyme level improved rapidly, and the skin findings gradually disappeared. In parallel, the patient's faecal occult blood test was positive, and lower gastrointestinal endoscopy revealed findings suggestive of advanced sigmoid colon cancer. Case 2; an 87-year-old female patient experienced myalgia in both upper limbs and thighs approximately 1 week after her first SARS-CoV-19 vaccination (manufactured by Pfizer). Primary care doctor who found a high myoglobin value (401.8 ng/ mL) referred her to our university hospital. Skin findings revealed oedema with slight erythema at bilateral eyelids and scaly erythema at a seborrheic lesion of the head and neck. Erythema with slight oedema and scratch marks were observed on her back (Fig. 2 ). There were no signs of Gottron papules or periungual erythema. General malaise and proximal muscle weakness (about MMT3) were observed predominantly in the upper arm. Histopathological examination of the erythema on her back was consistent with DM. Blood tests showed anti-TIF1-c antibodies and a high level of carbohydrate antigen 19-9. A commuted topography scan revealed a mass lesion in the ascending colon, and the possibility of DM with malignant tumour of the colon was considered as a diagnosis. Treatment with PSL 30 mg/kg (1 mg/kg) was initiated, and myogenic enzyme levels and skin lesions improved.

There have been several case reports of DM/PM in vaccinated patients, but the mechanisms are unclear and speculative. 3 genetic background; however, it is quite rare. In line with this, two cases in this present report were DM with anti-TIF1-c Ab positive and colon cancer. Of course, our DM cases may be based on malignancy, without relationship to the vaccine.

Various side effects have been reported following SARS-CoV-19 vaccination 4 and determining whether the onset of these side effects is different from other vaccines is critical. Future data collection is crucial for us, dermatologists, to discover the connection between SARS-CoV-19 vaccinations and skin symptoms.

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patients have given their consent for the publication of their images and other clinical information in the journal. They understand that their name and initial will not be published, and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

None.

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

A. Yoshida, T. Ikegami, K. Igawa* Department of Dermatology, School of Medicine, Dokkyo Medical University, Tochigi, Japan *Correspondence: K. Igawa. E-mail: igawa@dokkyomed.ac.jp

Infections and vaccinations as possible triggers of inflammatory myopathies

Environmental triggers of dermatomyositis: a narrative review

A review on the association between inflammatory myopathies and vaccination

Cutaneous findings following COVID-19 vaccination: review of world literature and own experience